Navigation Links
New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis

Second Multinational Phase III Study Provides Further Evidence of the Significant Role of IL-6 Receptor Inhibition in the Treatment of Rheumatoid Arthritis

BASEL, Switzerland, June 6, 2007-Roche announced today that Toward (1), the second multinational phase III Actemra (tocilizumab) study, successfully reached its primary endpoint and showed that a greater proportion of patients treated with Actemra in combination with traditional disease modifying drugs (DMARDs) achieved a significant improvement in disease signs and symptoms at week 24, compared to the those treated with DMARDs alone. The patients' symptoms were measured using the standard ACR score (2) assessment method. The patients enrolled in the study had active, moderate to severe rheumatoid arthritis (RA) and had experienced an inadequate response to DMARDs.

"The TOWARD trial data further documents the efficacy and safety of Actemra and the value of its IL-6 receptor inhibition. We look forward to further results from this extensive multinational Phase III development programme," commented William Burns, CEO Division Roche Pharmaceuticals.

The TOWARD trial included approximately 40% of patients from the United States and data from this trial will be submitted for presentation at international scientific meetings later this year and in 2008. TOWARD is the second of a programme of five phase III clinical trials running on Actemra, with two other trials due to report later in 2007. In January 2007 Roche reported that OPTION (3), the first of the phase III trials outside Japan, had successfully met its primary endpoint in patients who had an inadequate response to methorexate.

About the TOWARD study The TOWARD (Tocilizumab in cOmbination With traditional DMARD therapy) study was an international study treating 1216 patients with moderate to severe RA. The study was conducted at 130 study sites in 18 countries, including the USA. In th
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients
4. Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases
5. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
6. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
7. New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
10. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:9/29/2014)...  Following US and European approvals of Elekta,s ... Drug Administration (CFDA) has cleared the radiation therapy system ... According to the International Agency for Research on Cancer, ... every year in China 1 ... liver and esophageal cancers 2 . Versa HD is ...
(Date:9/29/2014)... Research and Markets has announced the ... and Forecasts, 2012-2018" report to their offering. ... billion by 2016. The North American segment accounts for nearly ... Europe claims approximately 30% (2018). Asia-Pacific ... of 11.4% driving a market value of US$728 million by ...
(Date:9/29/2014)... 29, 2014  On Oct. 2, some 24,000 Lilly ... company,s seventh Global Day of Service. Building on Lilly,s ... together in a single, coordinated effort to improve the ... "I,m so proud of this tradition, and of ... to strengthening the communities around the world where we ...
Breaking Medicine Technology:Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 2Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 3Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 2Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 3Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 4Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 5Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries 2Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries 3
... affiliated medical groups -- Sharp Rees-Stealy and Sharp Community ... possible designation for quality care given by the California ... 2011 Standards of Excellence program. CAPG is one of ... groups. "We are grateful to be recognized ...
... Calif., Sept. 20, 2011 CMC Biologics and ... companies have entered into a long-term commercial supply ... intravenous recombinant factor IX (rFIX) product, for the ... hemophilia B. Under the terms of the agreement, ...
Cached Medicine Technology:Sharp HealthCare Medical Groups Recognized for "Elite" Care 2Sharp HealthCare Medical Groups Recognized for "Elite" Care 3CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 2CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 3
(Date:9/30/2014)... AutoTex PINK proudly offers pink ... in support of breast cancer awareness and research in ... non-profits to “go pink” -- supporting walks, runs and ... a woman-owned company that is among the nation’s leading ... partnering with their customers to raise breast cancer awareness ...
(Date:9/30/2014)... DC (PRWEB) September 30, ... **MEDIA ADVISORY** , From:        Hope ... Barnwell, 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org ... Hope® Celebration , Date:        Thursday, ... Address:    The Army and Navy ...
(Date:9/30/2014)... Every New Year begins with a Resolution that will soon be ... effort, however most are out of mind in 30. Why? , ... of "spend more time with children", try something easy to do ... a reminder, daily life gets in the way and efforts to ... Goals out of sight equals goals out of mind. , ...
(Date:9/30/2014)... Miraca Life Sciences (MLS), the nation’s largest ... at the annual meeting of the American College of ... Scientific Meeting and Postgraduate Course in Philadelphia, Pa., on ... Life Sciences will be at booth 711 to share ... The research posters for ACG provide a wide range ...
(Date:9/30/2014)... Youth Town’s annual BBQ/Music Festival will take place ... at the Youth Town campus (3641 Youth Town Road ... festival, which will offer music, food and games. Admission ... show, arts and crafts fair, music, championship barbeque competition, ... McQueen and Mater from the hit Disney movie “Cars” ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2Health News:Miraca Life Sciences Research Institute to Present Eight GI Pathology Research Studies at Annual Meeting of American College of Gastroenterologists 2
... with advanced prostate cancer suggest they can be good ... study found a 20-year survival rate for 80 percent ... beyond the prostate, known as cT3 prostate cancer, and ... prostate gland. Previously, patients found to have cT3 prostate ...
... using cells from the interior of the nose could help ... treatable stages, according to a study conducted by researchers ... ATS 2011 International Conference. "Our data suggests that evaluating ... surface of the nose may serve as a non-invasive approach ...
... As Americans head toward attics, roofs and yards to freshen ... cleaning can lead to a spring visit to the hospital. ... on a stepladder, and more than 41,000 suffered injuries while ... Product Safety Commission. In addition, over 127,000 were injured while ...
... databases in 2010, researchers looked at the distribution ... health departments or national organizations (such as The ... Association/American Stroke Association). They found that 24 percent ... Notably, in the eight states that have ...
... --,Caring for a loved one who is ill is always ... dementia may face an increased risk for cognitive problem or ... the May issue of the Journal of the American ... their own mental health and ability to care for their ...
... , FRIDAY, May 13 (HealthDay News) -- Chest compressions ... of chest injury, according to new research. The ... Journal of Manipulative and Physiological Therapeutics , measured and ... extremely rigorous and found all to be well under the ...
Cached Medicine News:Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 2Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 3Health News:Spring Cleaning Lands Many Americans in Hot Water 2Health News:Older Caregivers at Greater Risk for Cognitive Decline 2Health News:Chiropractic Spinal Manipulation Won't Cause Chest Injuries, Study Contends 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: